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Abstract
Background:  Recent evidence suggests that estrogen signaling may be involved in the
pathogenesis of non-sma l l  c e l l  l u n g  c a n c e r  ( N S C L C ) .  A r o m a t a s e  i s  a n  e n z y m e  c o m p l e x  t h a t
catalyses the final step in estrogen synthesis and is present in several tissues, including the lung. In
the current study we investigated the activity of the aromatase inhibitor exemestane in human
NSCLC cell lines H23 and A549.
Results: Aromatase expression was detected in both cell lines. H23 cells showed lower protein
and mRNA levels of aromatase, compared to A549 cells. Exemestane decreased cell proliferation
and increased apoptosis in both cell lines, 48 h after its application, with A549 exhibiting higher
sensitivity than H23 cells. Aromatase protein and mRNA levels were not affected by exemestane
in A549 cells, whereas an increase in both protein and mRNA levels was observed in H23 cells, 48
h after exemestane application. Moreover, an increase in cAMP levels was found in both cell lines,
15 min after the administration of exemestane. In addition, we studied the effect of exemestane on
epidermal growth factor receptor (EGFR) localization and activation. Exemestane increased EGFR
activation 15 min after its application in H23 cells. Furthermore, we demonstrated a translocation
of EGFR from cell membrane, 24 h after the addition of exemestane in H23 cells. No changes in
EGFR activation or localization were observed in A549 cells.
Conclusion: Our findings suggest an antiproliferative effect of exemestane on NSCLC cell lines.
Exemestane may be more effective in cells with higher aromatase levels. Further studies are needed
to assess the activity of exemestane in NSCLC.
Background
Lung cancer is the most common cause of cancer mortal-
ity for both men and women in the United States and
non-small cell lung cancer (NSCLC) accounts for 80% of
all cases. The etiology of NSCLC has not yet been effi-
ciently elucidated. Recent evidence suggests that estrogen
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signaling is critical for the progression of malignancies
that express estrogen receptors (ER) and may also be
involved in the pathogenesis of NSCLC [1-7]. In a recent
review, Dubey et al [8] suggest that a number of principles
related to the pathogenesis or even the management of
the disease, may apply to both breast and lung carcinoma.
Despite previous conflicting data, recent studies have
indicated that estrogen receptors alpha (ERα) and beta
(ERβ) are overexpressed in certain proportions of malig-
nant lung cells [3,5-7,9]. Moreover, stimulation of cell
proliferation with estrogens has been reported in lung
cancer tissue cultures, further supporting the potential
biologic role of ERs in lung carcinogenesis [3-6]. A differ-
ence of ER expression between men and women has been
reported in lung cancer by Fasco et al, who found higher
levels of ER in female patients [10]. In addition, women
with lung cancer have also higher levels of estrogens com-
pared to healthy females of the same age [11]. It has been
hypothesized that estrogens may interact with carcino-
genic components of tobacco, affecting the risk for lung
cancer development. A positive association between exog-
enous and endogenous exposure to estrogens and the
development of lung adenocarcinoma has been described
in women [1], even though other studies have failed to
show such a correlation [12]. Furthermore, hormone
replacement therapy has been associated with shorter sur-
vival in lung cancer patients [11,13]. Recent data have also
provided evidence for an association between estrogen
levels and outcome, and this correlation may possibly
contribute to the survival advantage seen in older women
with NSCLC [14].
Given the accumulating data relating to the significance of
hormonal pathways in NSCLC, a role for antiestrogen
treatments in the management of the disease should not
be excluded. Although tamoxifen has been evaluated in
combination with chemotherapy in patients with NSCLC
[15,16], the agonistic activity of this agent on the ER
might limit its usefulness in lung cancer [3,4,11]. Moreo-
ver, clinical studies using tamoxifen in breast cancer
patients have not shown a reduction in lung cancer inci-
dence [17]. Fulvestrant is a pure antiestrogen which has
shown antiproliferative activity in estrogen-induced
growth of lung cancer cells [3,5]. In view of a possible
functional interaction between the ER and the epidermal
growth factor receptor (EGFR) pathways in NSCLC, ful-
vestrant has also been evaluated in combination with
EGFR tyrosine-kinase inhibitors (TKIs), both in NSCLC
xenografts [4,9] and in women with NSCLC [18], with
promising results. Similar studies evaluating the combina-
tion of fulvestrant with other TKIs are under way.
Assuming that lung cancer is responsive to hormonal
manipulations, another modality to alter estrogen signal-
ing could be via estrogen synthesis inhibition. Aromatase
is a cytochrome P450 enzyme complex that mediates the
final, rate-limiting step in estrogen synthesis. More specif-
ically, aromatase catalyzes three consecutive hydroxyla-
tion reactions converting C19 androgens to aromatic C18
estrogens. Upon receiving electrons from NADPH-cyto-
chrome P450 reductase, aromatase converts androstene-
dione and testosterone to estrone and estradiol,
respectively [19]. Apart from its expression in the ovaries,
the enzyme is also present in other tissues such as breast,
lung, liver and brain. Aromatase expression has been
recently demonstrated in NSCLC tumour specimens [5,7],
which could represent a local source of estrogen produc-
tion in lung cancer tissue in both genders.
Aromatase inhibitors (AIs) might also be effective in
NSCLC by reducing the biosynthesis of estrogens and
thereby inhibiting estrogen-depended pathways in lung
tumours. Currently, there are two classes of third-genera-
tion aromatase inhibitors: reversible nonsteroidal inhibi-
tors, such as anastrozole and letrozole, and irreversible
steroidal inactivators, such as exemestane. Exemestane
inhibits aromatization in vivo by about 98 percent in post-
menopausal breast cancer patients. In the adjuvant set-
ting, switching to exemestane after 2-3 years of adjuvant
tamoxifen was more effective than continuing tamoxifen
[20]. In this trial, patients assigned to exemestane dis-
played a trend of lower incidence of subsequent primary
lung cancer compared to those maintained on tamoxifen
(4 vs 12).
In the current study, we investigated the anti-tumour
activity of exemestane in lung cancer cell lines H23 and
A549 on cell proliferation and apoptosis. In addition, we
examined the effect of exemestane on aromatase activity
and expression levels. We also tested the hypothesis that
exemestane might exert its effect on aromatase activity
through a cAMP-dependent mechanism. Finally, we eval-
uated the effect of exemestane on EGFR localization and
activation.
Results
In vitro experiments were performed in two NSCLC cell
lines, H23 and A549. Both cell lines express ERα and ERβ
[3,5,7]. H23 cells express higher levels of ERα compared
to A549 cells, whereas the latter cell line expresses higher
levels of ERβ compared to H23 cells [7].
Aromatase expression in H23 and A549 cells
A549 cells express higher protein and mRNA aromatase
levels than H23 cells (Fig. 1 and Fig. 2). Aromatase activity
was detected in both cell lines. Exemestane did not affect
protein nor mRNA levels of aromatase in A549 cells, 48 h
after its application. In contrast, protein and mRNA levelsMolecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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were increased in H23 cells, 48 h after its application (Fig.
1 and Fig. 2).
Exemestane inhibited H23 and A549 cell growth and 
increased apoptosis
We studied the effect of exemestane on the proliferation
of the human NSCLC cell lines, H23 and A549. Exemes-
tane inhibited cell proliferation in both cell lines in a dose
dependent manner, 48 h after its application (Fig. 3a).
Fifty percent growth inhibition was recorded at 50 μM for
H23 and 20 μM for A549. All further experiments for each
cell line were performed with these concentrations of
exemestane. Moreover, evaluating the effect of testoster-
one on proliferation of H23 and A549 cells, we found that
testosterone did not affect cell proliferation at lower doses
whereas it decreased cell number at higher doses (Fig. 3b).
Furthermore, the percentage of annexin+ cells increased 48
h after treatment of H23 or A549 with exemestane com-
pared to untreated cells (Fig. 4). Although there are data
regarding cell cycle arrest by aromatase inhibitors in
breast cancer cells [21], a similar effect was not found with
exemestane in NSCLC cell lines in our study (data not
shown).
Aromatase activity in H23 and A549 cells
As aromatase catalyses the conversion of androstenedione
and testosterone to estrone and estradiol, respectively, its
activity was determined by the production of estradiol
after treatment of cells with exemestane. H23 and A549
cells were treated with exemestane without exogenous
addition of testosterone at the indicated concentrations,
and 15 min later estradiol production was measured. Pre-
vious reports have indicated that the estimated time for
achieving 50% of aromatase inhibition by exemestane is
13.9 min [19,22]. We found that a 15 min treatment with
exemestane caused a non-significant reduction of estra-
diol levels in both cell lines (Fig. 5a). However, estradiol
levels were increased 6, 8, 12, 24 and 48 h later in both
cell lines (Fig. 5a).
Furthermore, aromatase activity was determined at 6, 8,
12 and 24 h, following treatment of both cell lines with 1
μM testosterone. This experiment was used as an internal
control. The time point of 15 min was not used since there
are previous data showing that in breast cancer cells, aro-
matase is activated 6 h after incubation with a suitable
substrate [23]. As was expected, we found that application
of testosterone increased the levels of estradiol (Fig. 5b),
with the maximum production of estradiol being
observed 12 h after treatment of cells with the substrate.
cAMP levels in H23 and A549 cells
Evaluating the effect of exemestane on cAMP levels, we
found an increase of cAMP levels in both cell lines, 15 min
after treatment of cells with exemestane. This effect was
The effect of exemestane on protein levels of aromatase in H23 and A549 cells Figure 1
The effect of exemestane on protein levels of aromatase in H23 and A549 cells. A: H23 and A549 cells were 
treated with 50 μM and 20 μM exemestane respectively and 48 h later, cells were lysed and analyzed in SDS-PAGE. Actin was 
used as an internal control. The figure is a representative from at least three independent experiments. B: Quantification of 
western blot images. The results are expressed as % change of control. Asterisks denote a statistically significant difference 
(unpaired t-test) compared to control. * P < 0.05.Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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reversed 30 min after the application of exemestane (Fig.
6).
Localization and phosphorylation levels of EGFR in H23 
and A549 cells
Finally, we evaluated the effect of exemestane on EGFR
localization and activation. In A549 cells, no changes in
EGFR localization (Fig. 7) or phosphorylation (data not
shown) were demonstrated following treatment of cells
with exemestane. However, in H23 cells we found a trans-
location of EGFR from the cell membrane, 24 h after the
addition of exemestane (Fig. 7). Moreover, we demon-
strated an increase in EGFR activation, 15 min after treat-
ment of H23 cells with exemestane (Fig. 8a and 8b). EGFR
activation was detected using an Elisa kit assay (Fig. 8a),
and the results were confirmed by immunoblot analysis
(Fig. 8b).
Discussion
In the current study, we evaluated the activity of exemes-
tane in NSCLC cell lines H23 and A549. Our results are in
agreement with previous studies [5,7] which have
reported that aromatase is expressed by NSCLC cells. Lung
cancer cells may use estrogens produced via aromatase as
a way to maintain or even increase the ER signaling [24].
We have also found that exemestane inhibited cell prolif-
eration in both cell lines in a dose dependent manner and
apoptosis was increased without affecting cell cycle. Previ-
ous reports have indicated that AIs such as anastrozole
and letrozole may inhibit proliferation of the breast can-
cer cell line MCF-7 through induction of apoptosis and
cell cycle arrest [21].
In order to determine the effective dose of exemestane
regarding cell proliferation, a set of dose dependent exper-
iments were performed. The dose dependent curves
revealed that 50% growth inhibition was recorded at 50
μM for H23 and 20 μM for A549 cells. Although the
selected concentrations seem to be high, similar concen-
trations of an AI have also been used in previous studies
for in vitro experiments [7,25]. The dose of exemestane
currently used in clinical practice is 25 mg daily. Exemes-
tane exhibits an excellent safety profile in humans, having
no significant toxicity at doses up to 600 mg/day and it is
exceptionally well tolerated. The maximum tolerated dose
and dose limiting toxicities have yet to be identified [26].
At a single dose of 25 mg, the average peak plasma level is
18 ng/ml (approximately 0.06 nM), within 2 h post dos-
ing. This concentration is clearly lower compared to our in
vitro experimental model, as well as to the majority of
other in vitro experimental models. However, the aim of
our study was to focus on the effect of exemestane on aro-
matase activity and EGFR signalling, when used at a dose
with a significant effect on lung cancer cell proliferation.
In another study which also investigated the efficacy of an
AI in NSCLC, aromatase activity was inhibited by anastro-
zole in NSCLC cell lines, and treatment of tumour cells
with anastrozole led to suppression of cell growth [7]. It is
of interest that the use of an aromatase inhibitor has the
same effect on cell growth despite the different nature of
the inhibitors used. In fact, anastrozole is a reversible non-
steroidal inhibitor whereas exemestane is an irreversible
steroidal inactivator. In addition, our data provide infor-
mation with respect to the effect of exemestane on protein
and mRNA levels of aromatase in NSCLC cell lines.
Previous data regarding the effect of estradiol on the pro-
liferation of H23 and A549 cells are contradictory. When
estradiol was used at concentrations up to 1 μM, no effect
on cell proliferation was demonstrated [27]. In contrast,
estradiol enhanced cell proliferation when working con-
centrations were up to 20 μM [7]. Therefore, we decided
to treat both cell lines with various concentrations of tes-
tosterone, an aromatase substrate. We found that admin-
istration of testosterone did not affect the proliferation of
cells. However, treatment with testosterone at higher
doses was associated with a decrease in cell proliferation.
The effect of exemestane on mRNA levels of aromatase in  H23 and A549 cells Figure 2
The effect of exemestane on mRNA levels of aro-
matase in H23 and A549 cells. H23 and A549 cells were 
treated with 50 μM and 20 μM exemestane respectively and 
48 h later, aromatase mRNA levels were studied with real 
time RT-PCR. Results are expressed as relative expression 
and normalized to untreated cells. Asterisks denote a statisti-
cally significant difference (unpaired t-test) compared to 
untreated cells. * P < 0.05.Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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In view of the fact that testosterone is converted to estra-
diol by aromatase, the latter finding seems conflicting.
However, previous reports have indicated that estrogens
may reduce cell proliferation. Recent data suggest that
estrogens are capable of inducing apoptosis in certain cell
types, including breast cancer cells, immune system cells
and bone-derived cells [28,29].
Although exemestane showed a trend to inhibit aro-
matase activity 15 min after its application in both cell
cultures, this inhibitory effect was reversed 6 h later. Pre-
vious reports with aminoglutethimide, an AI, also showed
an increase in aromatase activity in breast cancer cell line
SK-BR-3, choriocarcinoma cell line JAR, and in hepatocel-
lular carcinoma HepG2 [30]. At least three mechanisms
have been suggested. The first is that AIs can stabilize aro-
matase protein by forming enzyme-inhibitor complexes
that slow down the degradation of the enzyme [31].
Indeed, we found an increase of aromatase protein levels
in H23 cells. Another mechanism is that AIs can modulate
aromatase expression at the transcription level [30]. In
our study, we observed an increase of aromatase mRNA
levels in H23 cells. On the other hand, we didn't find the
same changes in protein and mRNA levels in A549 cells.
The third possible mechanism includes changes in aro-
matase activity through a cAMP-dependent mechanism,
without affecting mRNA or protein expression of the
enzyme [30]. Indeed, in our study we demonstrated that
treatment of cells with exemestane increased the levels of
cAMP in both cell lines, 15 min after the application of the
agent. These findings suggest that exemestane may
increase the activity of aromatase through a cAMP-
dependent mechanism.
Although the decrease in aromatase activity was assessed
15 min following exemestane application, and this effect
was reversed 6 h after the administration of the drug,
changes in cell proliferation and aromatase protein and
mRNA levels were measured 48 h after the addition of
exemestane. Based on the information that the half life of
aromatase protein is 28.2 h [32], we believe that the
results from the inhibitory effect of exemestane could be
observed 48 h after drug application.
In a recently reported study [24] that assessed the prog-
nostic role of aromatase expression in NSCLC patients,
lower levels of the enzyme predicted a higher probability
of survival in women aged 65 years or older. These find-
ings suggest that older female patients with NSCLC and
high levels of aromatase might represent a group of
patients where treatment with an AI could be beneficial.
In our study, we showed that the cell line A549, which
expresses higher aromatase protein and mRNA levels
might be a better target for exemestane, since aromatase
Dose response of a) exemestane and b) testosterone in H23 and A549 cells Figure 3
Dose response of a) exemestane and b) testosterone in H23 and A549 cells. Different doses of exemestane or tes-
tosterone were applied on H23 and A549 cells and 48 h later, the number of cells was estimated with the colorimetric MTT 
assay. Results are expressed as mean ± SEM of the number of cells from at least three independent experiments performed in 
triplicates. Asterisks denote a statistically significant difference (unpaired t-test) compared to untreated cells. **P < 0.01 and 
***P < 0.001.Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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expression was not increased by this agent, in contrast to
the cell line H23 with lower aromatase levels. Moreover,
fifty percent growth inhibition was recorded at 50 μM for
H23 and 20 μM for A549 cells.
Finally, we found that the administration of exemestane
in H23 cells was associated with EGFR activation, 15 min
after drug application. Current evidence suggests that
cross-talk between steroid receptors and growth factor
receptors exists in a bidirectional way. In addition, signif-
icant interactions between estrogen signaling and EGFR
have been recognized not only in breast, but also in
NSCLC [5]. Exemestane may affect EGFR pathway inde-
pendently of aromatase inhibition. It has been demon-
strated that exemestane can activate ER [33] which in turn
leads to the production of the EGFR ligand amphiregulin,
resulting in EGFR activation [34]. This mechanism may be
implicated in exemestane resistance and may also be
involved in exemestane-induced EGFR activation found
in our study. Other interactions between growth factor
signaling pathways and aromatase in NSCLC have also
been reported [35]. The effect of exemestane on EGFR
activation observed in our study also suggests that this
agent may be less effective in H23 cells, compared to A549
cells. In addition, the combination of exemestane with an
anti-EGFR agent may represent a more efficient option in
H23 cells. Recently, we investigated the dual inhibition of
aromatase and EGFR in NSCLC cell lines using exemes-
tane and the EGFR tyrosine kinase inhibitor erlotinib. In
agreement with the aforementioned results, the combina-
tion of exemestane and erlotinib was more effective than
each agent alone, in H23 cells [36].
The activation of EGFR followed by its translocation may
lead to receptor internalization and proteolytic degrada-
tion [37]. Alternatively, EGFR has been detected in caveo-
lae, Golgi complex, endoplasmatic reticulum, lysosome-
like structures, nuclear envelope, nucleus and mitochon-
dria [38,39]. In addition, it has been demonstrated that
EGFR mitochondrial localization is implicated in cell sur-
vival [39]. In agreement with this observation, unpub-
lished data from our laboratory confirmed the
translocation of EGFR to mitochondria in H23 cells, fol-
lowing treatment with exemestane. Moreover, this trans-
location was inhibited by the concurrent administration
of erlotinib.
In summary, our results suggest that exemestane might
elevate estradiol levels in both cell lines through a cAMP-
dependent mechanism. In addition, exemestane enhances
estradiol levels in H23 cells through an increase in mRNA
and protein levels of aromatase. However, the antiprolif-
erative effect of exemestane through induction of apopto-
sis remains to be elucidated. A recent report demonstrated
The effect of exemestane on apoptosis of H23 and A549 cells Figure 4
The effect of exemestane on apoptosis of H23 and A549 cells. A: Flow cytometry analysis of H23 and A549 following 
exposure to exemestane. A representative image from three independent experiments is shown. H23 cells. C: Control and E 
50 μM: Exemestane 50 μM. A549 cells. C: Control and E 20 μM: Exemestane 20 μM. B: Results are expressed as the % per-
centage of Annexin+ cells ± SEM compared to untreated cells from at least three independent experiments. Asterisks denote a 
statistically significant difference (unpaired t-test) compared to untreated cells (C). ** P < 0.01 and *** P < 0.001.Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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that high concentrations of estradiol, under low growth
stimulated conditions, decrease cell proliferation and
increase apoptosis in breast cancer cells through the sus-
tained activation of JNK pathway [40]. Indeed, our exper-
iments were performed under low growth stimulated
conditions which mimic the low estrogenic milieu in
postmenopausal women [40]. This mechanism may rep-
resent a possible explanation for the antiproliferative
effect of exemestane in both NSCLC cell lines, found in
our study.
Conclusion
In conclusion, our study provides evidence that aromatase
is expressed by NSCLC cells and exemestane inhibits cell
proliferation. Moreover, levels of aromatase expression
might have a predictive ability in the activity of this agent,
since exemestane may activate EGFR pathway in cells with
low levels of aromatase. Further studies are needed to
investigate the effectiveness of exemestane in NSCLC and
evaluate the potential for incorporating AIs in the man-
agement of lung cancer patients.
Methods
Cell culture and reagents
NSCLC cell lines H23 and A549, and control breast cancer
cell line MCF-7 were purchased from American Type Cul-
ture Collection (ATCC). H23 and A549 cells were cultured
in RPMI 1640 medium with 2 mM L-glutamine and sup-
plemented with 1 mM sodium pyruvate, 4.5 g/L glucose,
1.5 g/L sodium bicarbonate and 10% fetal bovine serum.
MCF-7 cells were cultured in Eagle's Minimum Essential
medium (EMEM) with Earle's BSS and 2 mM L-glutamine
and supplemented with 1.0 mM sodium pyruvate, 0.1
mM nonessential amino acids, 1.5 g/L sodium bicarbo-
nate, 0.01 mg/ml bovine insulin and 10% fetal bovine
serum. Cells were cultured at 37°C, 5% CO2 and 100%
humidity.
The aromatase inhibitor exemestane (Aromasin) was
kindly provided by Pfizer. Exemestane was applied to cell
lines after cell attachment at doses of 1, 5, 10, 20 and 50
μM. Testosterone was purchased by Sigma (Sigma, Stein-
heim, Germany) and was applied to cell lines after cell
attachment at doses of 0.001, 0.01, 0.1, 1, 10 and 50 μM.
Exemestane was diluted in dimethyl sulfoxide (DMSO)
and testosterone was diluted in ethanol. The final concen-
tration of both DMSO and ethanol in culture medium was
The effect of a) exemestane and b) testosterone on aromatase activity of H23 and A549 cells Figure 5
The effect of a) exemestane and b) testosterone on aromatase activity of H23 and A549 cells. H23 and A549 cells 
were treated with 50 μM and 20 μM exemestane, respectively and both cell lines were treated with 1 μM testosterone. At the 
time points of 15 min, 6, 8, 12, 24 and 48 h, samples were analysed as described in Methods. *P < 0.05, ** P < 0.01 and *** P < 
0.001.Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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0.5%. After reaching 50% confluence, cells were washed
with phosphate buffer saline (PBS) and incubated with
phenol red-free medium with 1% dextran-coated, char-
coal-treated FBS (working medium) for 24 h to deplete
estrogen [7]. All the experiments were performed accord-
ing to these conditions. Thereafter, cells were treated with
exemestane or testosterone at the indicated time points
and doses.
Immunoblotting
Cells were plated at Petri dishes. After reaching 80% con-
fluence, cells were treated with working medium as
described above. Forty eight hours after exemestane addi-
tion, cells were collected with scrapper and lysed using
appropriate lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 5 mM EDTA, 1% Triton, 10% glycerol, 1 mM phe-
nylmethyl-sulphonyl-fluoride, 2 mM Na-orthovanadate
and 10 mM leupeptin). Protein concentration was deter-
mined by Bradford assay. Samples were analyzed by
immunoblotting as described previously [7]. Actin was
used as control. A goat polyclonal anti-aromatase anti-
body (CYP19) C16 (dilution 1:5000, Santa Cruz, CA,
USA) and a monoclonal anti-actin antibody were used
(dilution 1:1000, Chemicon, Millipore, Temecula, CA,
USA). For the detection of phosphorylated EGFR/EGFR,
an immunoprecipitation was performed prior to immu-
noblotting. Briefly, cells were prepared as described
above. Fifteen minutes after the addition of exemestane,
cells were collected with scrapper and lysed with sonica-
tion (3 cycles for 5 sec each, MSE PG 616) using the same
lysis buffer as above. Protein concentration was deter-
mined and 1 mg total protein was immunoprecipitated
with a monoclonal anti- EGFR antibody (dilution 1 μg per
0.5 mg of total protein, 3H2094, Santacruz, CA, USA),
overnight at 4°C under continuous agitation. In each
sample, 50 μl of protein-A sepharose beads (Calbiochem,
Merck, Dermstadt, Germany) were added and samples
were incubated for 4 h, at 4°C under continuous agita-
tion. Precipitates were washed twice with ice-cold lysis
buffer and sepharose beads were resuspended in 50 μl 2×
sample buffer (0.5 M Tris-HCl pH 6.8, 20% glycerol, 2%
SDS and 2% bromophenol blue, 10% b-mercaptoetha-
nol). Samples were heated for 5 min at 95°C and ana-
lyzed by immunoblotting. A monoclonal anti-tyrosine
antibody (dilution 2 μg/ml, Upstate, Lake Placid, NY,
USA) and a monoclonal anti-EGFR antibody (dilution
1:200, 3H2094, Santacruz, CA, USA) were used. Detec-
tion of immunoreactive proteins was performed by
chemiluminescence using horseradish peroxidase sub-
strate SuperSignal (Pierce, Rockford, IIL, USA), according
to manufacturer's instructions.
RNA isolation and cDNA synthesis
Total RNA was extracted from cells using Absolutely RNA
RT-PCR kit (Stratagene, La Jolla, USA) according to the
manufacturer's instructions. Integrity of RNA was con-
firmed by visualization of ribosomal bands by EtBr-
stained agarose gel electrophoresis. RNA was quantified
using Ribogreen (Molecular Probes, Leiden, the Nether-
lands) and the MX3000p (Stratagene, La Jolla, USA)
according to manufacturer's instructions. First strand
cDNA was synthesized as previously described [41].
Real time PCR
Quantification of cyp19 mRNA was performed using
gene-specific primers (F: 5'-AACAACTCGACCCTTCTT-
TATG-3', R: 5'-TTTGAGGGATTCAGCACAG-3') and SYBR
Green I intercalation dye in Brilliant Sybr Green QPCR
Master Mix (Stratagene, La Jolla, USA). Expressed Alu-Sq
repeat levels were also similarly quantified using primers
designed by Dr J. Vandesompele, Gent University Hospi-
tal, Belgium. In addition, a standard curve was included in
each run for assay validation. Reactions were performed as
previously described [41]. Cyp19 mRNA levels were nor-
malised to Alu-Sq levels which were found to be unaf-
fected by exemestane treatment.
Cell proliferation assay
To determine whether exemestane or testosterone affect
the proliferation of H23 and A549 NSCLC cell lines, the
3- [4,5-dimethylthiazol-2-yl]-2,5-dimethyltetrazolium
bromide (MTT) assay was used, as previously described
[42]. Briefly, cells were plated at a density of 2 × 104 cells
per well in 24-well tissue culture plates. The medium was
aspirated later at 24 h, cells were washed twice with phos-
The effect of exemestane on cAMP levels in H23 and A549  cells Figure 6
The effect of exemestane on cAMP levels in H23 and 
A549 cells. H23 and A549 cells were treated with 50 μM 
and 20 μM exemestane, respectively. At the time points of 
15 and 30 min, samples were analysed as described in Meth-
ods. ** P < 0.01.Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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phate buffer saline (PBS) and 0.5 ml of working medium
was added in each well. After a 24 h incubation exemes-
tane or testosterone was added into cells. Cell prolifera-
tion was measured 48 h after exemestane addition using
MTT assay. MTT stock (5 mg/ml in PBS) at a volume equal
to 1/10 of the medium was added and plates were incu-
bated at 37°C for 2 h. The medium was removed, the cells
were washed with PBS pH 7.4 and 100 μl acidified isopro-
panol (0.33 ml HCl in 100 ml isopropanol) was added to
each well and agitated thoroughly in order to solubilise
the dark blue formazan crystals. The solution was trans-
ferred to 96-well plates and immediately read on a micro-
plate reader (Tecan, Sunrise, Magellan 2) at a wavelength
of 570 nm. Results were always confirmed by direct meas-
urements of the cells using a standard Neubauer haemo-
cytometer.
Apoptosis assay
Both NSCLC cell lines were plated at 1 × 105 cells per well
in 6-well plates. Exemestane was added as previously
described. At the end of a 48 h incubation, cells were
washed twice with PBS, trypsinized for 6 min and centri-
fuged for 4 min at 166 g. Cells were resuspended in 200 μl
1× binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl,
The effect of exemestane on EGFR localization in H23 and A549 cells Figure 7
The effect of exemestane on EGFR localization in H23 and A549 cells. Both cell lines were treated with 50 μM and 
20 μM exemestane, respectively. At the time point of 24 h, samples were analyzed as described in Methods. The figure is a rep-
resentative from at least three independent experiments (magnification at 60×).Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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2.5 mM CaCl2). The cell suspension was incubated with 5
μl Annexin V-FITC in the dark at 25°C, for 10 min. Then,
10 μl of the 20 μg/ml propidium iodide stock solution
was added, followed by 400 μl of binding buffer and cells
were immediately analyzed by flow cytometry [43]
(EPICS-XL of Coulter) according to manufacturer's
instructions (rh Annexin V/FITC kit, Bender MedSystems).
Aromatase activity
Aromatase activity was estimated through measurement
of estradiol production by ELISA (IBL Hamburg, Ger-
many) according to manufacturer's instructions at 450
nm with a microplate reader (Tecan, Sunrise, Magellan 2).
Briefly, cells were plated at 2 × 104 cells per well in 24-well
plates. Exemestane or testosterone was added as previ-
ously described. At several time points after incubation
(0.25, 6, 8, 12, 24 and 48 h), supernatants were collected
and stored at -20°C until the end of the experiment.
Twenty five μl of each sample was added into well that
was pre-coated with a polyclonal antibody against estra-
diol molecule. Then 200 μl of appropriate enzyme conju-
gate was added to each well and an incubation of 2 h was
followed. After the incubation, wells were washed 3 times
with wash solution and 100 μl of suitable substrate solu-
tion was added to each well. Fifteen minutes later, the
enzymatic reaction was stopped by adding 50 μl of stop
solution. The absorbance of each well was measured at
450 nm with a microplate reader within 10 min after add-
ing the stop solution. An appropriate standard curve was
determined.
cAMP detection
The cAMP levels were measured using an ELISA kit assay
(R&D Systems Europe, Ltd, UK). Samples were prepared
according to manufacturer's instructions. Briefly, H23 and
A549 cells were plated in Petri dishes. After reaching 50%
confluence, cells were treated with working medium as
described above and 24 h later exemestane was added into
cells. Supernatants were removed 15 and 30 min later and
cells were washed 3 times with cold PBS. Then, cells were
resuspended in cell lysis buffer 5 (1×) that was included in
kit to a concentration of 1 × 107 cells/ml. Cells were
freezed at ≤ -20°C and thawed with gentle mixing. The
cycle of freeze/thaw was repeated once. Samples were cen-
trifuged at 600 × g for 10 min at 4°C to remove cellular
debris. Samples were stored at -20°C until their use. Suit-
able microplate containg pre-coated wells with goat anti-
mouse antibody, was incubated with 50 μl of a mono-
clonal antibody specific for cAMP for 1 h at room temper-
ature. After the incubation, wells were washed 3 times
with wash solution and 100 μl of each sample was added
to each well. Then, 50 μl of cAMP congjugate was added
to all wells and an incubation of 2 h was followed. After a
step of 3 washes, 200 μl of a substrate solution was added
to each well and an incubation of 30 min in dark was fol-
lowed. Then, 100 μl of stop solution was added to each
The effect of exemestane on EGFR phosphorylation a) in H23 cells using an ELISA kit assay and b) in H23 and A549 cells using  immunoblotting Figure 8
The effect of exemestane on EGFR phosphorylation a) in H23 cells using an ELISA kit assay and b) in H23 and 
A549 cells using immunoblotting. H23 and A549 cells were treated with 50 μM and 20 μM exemestane, respectively and 
15 min later they were analyzed as described in Methods. C: untreated cells (H23 or A549 cells) and Exm: H23 or A549 cells 
treated with 50 μM or 20 μM exemestane, respectively. *P < 0.05.Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
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well. The absorbance of each well was measured at 450
nm with correction at 570 nm in a microplate reader
(Tecan, Sunrise, Magellan 2) within 30 min after adding
the stop solution. An appropriate standard curve was
determined.
Immunofluorescense
Both NSCLC cell lines were treated with exemestane as
previously described. Twenty four hours later, medium
was removed and cells were washed twice with PBS. Cells
were fixed with a 4% paraformaldehyde in PBS buffered
solution for 10 min at room temperature and then they
were rinsed 3 × 5 min with PBS. An incubation of 1 h was
followed by a 3% BSA solution supplemented with 10%
FBS at 37°C. After the incubation with blocking solution,
cells were rinsed once with PBS for 5 min and they were
treated overnight at 4°C with a monoclonal anti-EGFR
antibody diluted in blocking solution (10 μg/ml, Upstate,
Lake Placid, NY, USA,). Cells were rinsed 3 × 5 min with
PBS and then an anti-mouse antibody conjugated with
Alexa Fluor 594 (1:500, Invitrogen, Molecular probe)
diluted in blocking solution was added for 30 min at
37°C. Cells were rinsed 3 × 5 min with PBS and mounted
on glass sides. Fluorescence was visualized using a Leica
microscope.
EGFR phosphorylation
The levels of phosphorylated EGFR were determined
using an ELISA kit system (Bender MedSystems GmbH,
Austria), according to the manufacturer's instructions.
Briefly, cells were seeded in 100 mm petri dishes at a den-
sity of 106 cells per dish and were treated as previously
described. Fifteen minutes after the addition of exemes-
tane, supernatants were removed and cells were collected
with scraper. Lysis of cells was followed by adding recep-
tor binding buffer. Samples were transferred onto 96-
microwell plate coated with a monoclonal antibody to
human active EGFR and incubated for 1 h at 37°C. Micro-
wells were emptied and washed three times with washing
buffer. An anti-phosphotyrosine monoclonal antibody
(horseradish peroxidase conjugated) was added and sam-
ples were incubated for 1 h at 37°C. Microwells were
washed four times and a suitable substrate solution was
added to each sample for 15 min. The reaction was
stopped by adding a stop solution and the samples were
immediately measured on a microplate reader (Tecan,
Sunrise, Magellan 2) at a wavelength of 450 nm. The
results were normalized by measuring the amount of total
proteins using Bradford assay, since total protein amount
is not altered for the time point of 15 min after exemes-
tane addition.
Statistical analysis
Differences between groups and controls were tested by
unpaired t-test. Each experiment included at least tripli-
cate measurements. All results are expressed as mean ±
SEM from at least three independent experiments.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AKK participated in the conception, design and coordina-
tion of the study, interpretation of data, and drafted the
manuscript. EG participated in the design of the study and
interpretation of data, performed the analyses, and was
involved in drafting the manuscript. KI and AA contrib-
uted to the analyses and interpretation of data. TRJE and
AGP critically revised the manuscript. HPK participated in
the design and coordination of the study. All authors have
read and approved the final version of the manuscript.
Acknowledgements
EG and AA were supported by the Hellenic Cooperative Oncology Group 
(HeCOG).
References
1. Taioli E, Wynder EL: Re: Endocrine factors and adenocarci-
noma of the lung in women.  J Natl Cancer Inst 1994, 86:869-870.
2. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa
K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson JA,
Hayashi SI: Expression, function, and clinical implications of
the estrogen receptor β in human lung cancers.  Biochem Bio-
phys Res Commun 2001, 285:340-347.
3. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie
N, Finkelstein S, Siegfried JM: Human non-small cell lung
tumours and cells derived from normal lung express both
estrogen receptor alpha and beta and show biological
responses to estrogen.  Cancer Res 2002, 62:2141-2150.
4. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM:
Combined targeting of the estrogen receptor and the epi-
dermal growth factor receptor in non-small cell lung cancer
shows enhanced antiproliferative effects.  Cancer Res 2005,
65:1459-1470.
5. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M:
Estrogen and growth factor receptor interactions in human
breast and non-small cell lung cancer cells.  Steroids 2005,
70:372-381.
6. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM,
Nichols M: Regulation of endogenous gene expression in
human non-small cell lung cancer cells by estrogen receptor
ligands.  Cancer Res 2005, 65:1598-1605.
7. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Gar-
ban HJ, Dubinett SM, Pietras RJ: Aromatase inhibitors in human
lung cancer therapy.  Cancer Res 2005, 65:11287-11291.
8. Dubey S, Siegfried JM, Traynor AM: Non-small-cell lung cancer
and breast carcinoma: chemotherapy and beyond.  Lancet
Oncol 2006, 7:416-424.
9. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras
RJ:  Estrogen receptor signalling pathways in human non-
small cell lung cancer.  Steroids 2007, 72:135-143.
10. Fasco MJ, Hurteau GJ, Spivack SD: Gender-dependent expression
of alpha and beta estrogen receptors in human non-tumor
and tumor lung tissue.  Mol Cell Endocrinol 2002, 188:125-140.
11. Stabile LP, Siegfried JM: Estrogen receptor pathways in lung can-
cer.  Curr Oncol Rep 2004, 6:259-267.
12. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz
MR: Hormone replacement therapy and lung cancer risk: a
case-control analysis.  Clin Cancer Res 2004, 10:113-123.
13. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A: Hor-
mone replacement therapy is associated with decreased sur-
vival in women with lung cancer.  J Clin Oncol 2006, 24:59-63.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2009, 8:109 http://www.molecular-cancer.com/content/8/1/109
Page 12 of 12
(page number not for citation purposes)
14. Hede K: Lung cancer may be different for men and women,
but researchers ponder what to do?  J Natl Cancer Inst 2007,
99:1830-1832.
15. Yang CH, Cheng AL, Yeh KH, Yu CJ, Lin JF, Yang PC: High dose
tamoxifen plus cisplatin and etoposide in the treatment of
patients with advanced, inoperable non small cell lung carci-
noma.  Cancer 1999, 86:415-420.
16. Chen Y, Perng RP, Yang KY, Lin WC, Wu HW, Tsai CM, Whang-Peng
J: Phase II study of tamoxifen, ifosfamide, epirubicin and cis-
platin combination chemotherapy in patients with non-small
cell lung cancer failing previous chemotherapy.  Lung Cancer
2000, 29:139-146.
17. Patel JD, Gray RG, Stewart JA, Skinner HG, Schiller JH: Tamoxifen
does not reduce the risk of lung cancer in women [abstract].
J Clin Oncol 2005, 23:7212.
18. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S,
Hoang T, Dubey S, Marcotte SM, Siegfried JM: Pilot study of gefit-
inib and fulvestrant in the treatment of post-menopausal
women with advanced non-small cell lung cancer.  Lung Cancer
2009, 64:51-59.
19. Hong Y, Yu B, Sherman M, Yuan YC, Zhou D, Chen S: Molecular
basis for the aromatization reaction and exemestane medi-
ated-irreversible inhibition of human aromatase.  Mol Endocri-
nol 2007, 21:401-414.
20. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T,
Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dod-
well D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning
PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M,
Massimini G, Bliss JM, Velde C van de, Intergroup Exemestane Study:
A randomized trial of exemestane after two or three years
of tamoxifen therapy in postmenopausal women with pri-
mary breast cancer.  N Engl J Med 2004, 350:1081-1092.
21. Thiantanawat A, Long B, Brodie A: Signaling pathways of apopto-
sis activated by aromatase inhibitors and antiestrogens.  Can-
cer Res 2003, 63:8037-8050.
22. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, di Salle E: 6-
Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new
irreversible aromatase inhibitor.  J Steroid Biochem 1988,
30:391-394.
23. Santner SJ, Pauley RJ, Tait L, Kaseta J, Santen RJ: Aromatase activity
and expression in breast cancer and benign breast tissue
stromal cells.  J Clin Endocrinol Metab 1997, 82:200-208.
24. Mah V, Seligson DB, Li A, Mαrquez DC, Wistuba II, Elshimali Y, Fish-
bein MC, Chia D, Pietras RJ, Goodglick L: Aromatase expression
predicts survival in women with early-stage non-small cell
lung cancer.  Cancer Res 2007, 67:10484-10490.
25. Miller WR: Biology of aromatase inhibitors: pharmacology/
endocrinology within the breast.  Endocr Relat Cancer 1999,
6:187-195.
26. Brueggemeier RW: Overview of the pharmacology of the aro-
matase inactivator exemestane.  Breast Cancer Res Treat 2002,
74:177-185.
27. Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly
KA, Blankenship KA, Huff MO, McGregor WG, Klinge CM: Gender
difference in the activity but not expression of estrogen
receptors alpha and beta in human lung adenocarcinoma
cells.  Endocr Relat Cancer 2006, 13:113-134.
28. Jordan VC, Lewis JS, Osipo C, Cheng D: The apoptotic action of
estrogen following exhaustive antihormonal therapy: a new
clinical treatment strategy.  Breast 2005, 14:624-630.
29. Song RX, Santen RJ: Apoptotic action of estrogen.  Apoptosis
2003, 8:55-60.
30. Chen S, Zhou D, Yang C, Okubo T, Kinoshita Y, Yu B, Kao YC, Itoh
T: Modulation of aromatase expression in human breast tis-
sue.  J Steroid Biochem Mol Biol 2001, 79:35-40.
31. Harada N, Hatano O: Inhibitors of aromatase prevent degrada-
tion of the enzyme in cultured human tumor cells.  Br J Cancer
1998, 77:567-572.
32. Wang X, Chen S: Aromatase Destabilizer: Novel Action of
Exemestane, a Food and Drug Administration-Approved
Aromatase Inhibitor.  Cancer Res 2006, 66:10281-10286.
33. Masri S, Lui K, Phung S, Ye J, Zhou D, Wang X, Chen S: Character-
ization of the weak estrogen receptor alpha agonistic activ-
ity of exemestane.  Breast Cancer Res Treat 2009, 116:461-470.
34. Wang X, Masri S, Phung S, Chen S: The role of amphiregulin in
exemestane-resistant breast cancer cells: evidence of an
autocrine loop.  Cancer Res 2008, 68:2259-2265.
35. Marquez-Garbon DC, Chen HW, Goodglick L, Fishbein MC, Pietras
RJ: Targeting aromatase and estrogen signaling in human
non-small cell lung cancer.  Ann N Y Acad Sci 2009, 1155:194-205.
36. Koutras A, Kritikou I, Giannopoulou E, Dimitropoulos K, Kalofonos
H: Dual inhibition of aromatase and epidermal growth factor
receptor in non-small cell lung cancer [abstract].  J Clin Oncol
2009, 27:e22189.
37. Waterman H, Yarden Y: Molecular mechanisms underlying
endocytosis and sorting of ErbB receptor tyrosine kinases.
FEBS Lett 2001, 490:142-152.
38. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon
L, Hung MC: Nuclear localization of EGF receptor and its
potential new role as a transcription factor.  Nat Cell Biol 2001,
3:802-808.
39. Yue X, Song W, Zhang W, Chen L, Xi Z, Xin Z, Jiang X: Mitochon-
drially localized EGFR is subjected to autophagic regulation
and implicated in cell survival.  Autophagy 2008, 4:641-649.
40. Altiok N, Koyuturk M, Altiok S: JNK pathway regulates estra-
diol-induced apoptosis in hormone-dependent human breast
cancer cells.  Breast Cancer Res Treat 2007, 105:247-254.
41. Grivas PD, Antonacopoulou A, Tzelepi V, Sotiropoulou-Bonikou G,
Kefalopoulou Z, Papavassiliou AG, Kalofonos H: HER-3 in colorec-
tal tumourigenesis: From mRNA levels through protein sta-
tus to clinicopathologic relationships.  Eur J Cancer 2007,
43:2602-2611.
42. Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou A,
Kalofonos H: Dual targeting of EGFR and HER-2 in colon can-
cer cell lines.  Cancer Chemother Pharmacol 2009, 63:973-981.
43. Kuwada SK, Scaife CL, Kuang J, Li X, Wong RF, Florell SR, Coffey RJ
Jr, Gray PD: Effects of trastuzumab on epidermal growth fac-
tor receptor-dependent and -independent human colon can-
cer cells.  Int J Cancer 2004, 109:291-301.